PAREXEL Intl Corp.
PAREXEL Intl Corp. (PRXL) Stock Competitors & Peer Comparison
See (PRXL) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PRXL | $88.08 | +0.00% | 0 | N/A | N/A | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.71% |
| TMO | $491.46 | -0.62% | 182.6B | 27.69 | $17.75 | +0.36% |
| DHR | $191.12 | +0.17% | 135.1B | 38.00 | $5.03 | +0.71% |
| IDXX | $569.55 | +0.87% | 45.3B | 43.48 | $13.10 | N/A |
| A | $115.48 | +0.82% | 32.7B | 25.49 | $4.53 | +0.87% |
| NTRA | $207.98 | +2.35% | 29.5B | -136.83 | -$1.52 | N/A |
| IQV | $173.26 | +0.50% | 29.4B | 22.10 | $7.84 | N/A |
| MTD | $1,259.94 | -1.11% | 25.6B | 29.97 | $42.04 | N/A |
| LH | $273.72 | +0.36% | 22.7B | 26.17 | $10.46 | +1.05% |
Stock Comparison
PRXL vs DHR-PB Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, PRXL is priced at $88.08, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, PRXL's ROE is +0.17%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, PRXL is less volatile compared to DHR-PB. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check DHR-PB's competition here
PRXL vs TMO Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, TMO has a market cap of 182.6B. Regarding current trading prices, PRXL is priced at $88.08, while TMO trades at $491.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas TMO's P/E ratio is 27.69. In terms of profitability, PRXL's ROE is +0.17%, compared to TMO's ROE of +0.13%. Regarding short-term risk, PRXL is less volatile compared to TMO. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check TMO's competition here
PRXL vs DHR Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, DHR has a market cap of 135.1B. Regarding current trading prices, PRXL is priced at $88.08, while DHR trades at $191.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas DHR's P/E ratio is 38.00. In terms of profitability, PRXL's ROE is +0.17%, compared to DHR's ROE of +0.07%. Regarding short-term risk, PRXL is less volatile compared to DHR. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check DHR's competition here
PRXL vs IDXX Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, IDXX has a market cap of 45.3B. Regarding current trading prices, PRXL is priced at $88.08, while IDXX trades at $569.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas IDXX's P/E ratio is 43.48. In terms of profitability, PRXL's ROE is +0.17%, compared to IDXX's ROE of +0.70%. Regarding short-term risk, PRXL is less volatile compared to IDXX. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check IDXX's competition here
PRXL vs A Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, A has a market cap of 32.7B. Regarding current trading prices, PRXL is priced at $88.08, while A trades at $115.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas A's P/E ratio is 25.49. In terms of profitability, PRXL's ROE is +0.17%, compared to A's ROE of +0.20%. Regarding short-term risk, PRXL is less volatile compared to A. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check A's competition here
PRXL vs NTRA Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, NTRA has a market cap of 29.5B. Regarding current trading prices, PRXL is priced at $88.08, while NTRA trades at $207.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas NTRA's P/E ratio is -136.83. In terms of profitability, PRXL's ROE is +0.17%, compared to NTRA's ROE of -0.15%. Regarding short-term risk, PRXL is less volatile compared to NTRA. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check NTRA's competition here
PRXL vs IQV Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, IQV has a market cap of 29.4B. Regarding current trading prices, PRXL is priced at $88.08, while IQV trades at $173.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas IQV's P/E ratio is 22.10. In terms of profitability, PRXL's ROE is +0.17%, compared to IQV's ROE of +0.22%. Regarding short-term risk, PRXL is less volatile compared to IQV. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check IQV's competition here
PRXL vs MTD Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, MTD has a market cap of 25.6B. Regarding current trading prices, PRXL is priced at $88.08, while MTD trades at $1,259.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas MTD's P/E ratio is 29.97. In terms of profitability, PRXL's ROE is +0.17%, compared to MTD's ROE of -4.87%. Regarding short-term risk, PRXL is less volatile compared to MTD. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check MTD's competition here
PRXL vs LH Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, LH has a market cap of 22.7B. Regarding current trading prices, PRXL is priced at $88.08, while LH trades at $273.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas LH's P/E ratio is 26.17. In terms of profitability, PRXL's ROE is +0.17%, compared to LH's ROE of +0.10%. Regarding short-term risk, PRXL is less volatile compared to LH. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check LH's competition here
PRXL vs DGX Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, DGX has a market cap of 22B. Regarding current trading prices, PRXL is priced at $88.08, while DGX trades at $198.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas DGX's P/E ratio is 22.63. In terms of profitability, PRXL's ROE is +0.17%, compared to DGX's ROE of +0.14%. Regarding short-term risk, PRXL is less volatile compared to DGX. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check DGX's competition here
PRXL vs EXAS Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, PRXL is priced at $88.08, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas EXAS's P/E ratio is -95.37. In terms of profitability, PRXL's ROE is +0.17%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, PRXL is more volatile compared to EXAS. This indicates potentially higher risk in terms of short-term price fluctuations for PRXL.Check EXAS's competition here
PRXL vs ILMN Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, ILMN has a market cap of 19.5B. Regarding current trading prices, PRXL is priced at $88.08, while ILMN trades at $127.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas ILMN's P/E ratio is 23.37. In terms of profitability, PRXL's ROE is +0.17%, compared to ILMN's ROE of +0.35%. Regarding short-term risk, PRXL is less volatile compared to ILMN. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check ILMN's competition here
PRXL vs WAT Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, WAT has a market cap of 18.1B. Regarding current trading prices, PRXL is priced at $88.08, while WAT trades at $304.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas WAT's P/E ratio is 28.25. In terms of profitability, PRXL's ROE is +0.17%, compared to WAT's ROE of +0.29%. Regarding short-term risk, PRXL is less volatile compared to WAT. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check WAT's competition here
PRXL vs PKI Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, PRXL is priced at $88.08, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas PKI's P/E ratio is 41.45. In terms of profitability, PRXL's ROE is +0.17%, compared to PKI's ROE of +0.03%. Regarding short-term risk, PRXL is less volatile compared to PKI. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check PKI's competition here
PRXL vs MEDP Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, MEDP has a market cap of 14.1B. Regarding current trading prices, PRXL is priced at $88.08, while MEDP trades at $498.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas MEDP's P/E ratio is 32.66. In terms of profitability, PRXL's ROE is +0.17%, compared to MEDP's ROE of +1.19%. Regarding short-term risk, PRXL is less volatile compared to MEDP. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check MEDP's competition here
PRXL vs GH Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, GH has a market cap of 12.3B. Regarding current trading prices, PRXL is priced at $88.08, while GH trades at $93.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas GH's P/E ratio is -28.26. In terms of profitability, PRXL's ROE is +0.17%, compared to GH's ROE of +1.65%. Regarding short-term risk, PRXL is less volatile compared to GH. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check GH's competition here
PRXL vs RVTY Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, RVTY has a market cap of 9.9B. Regarding current trading prices, PRXL is priced at $88.08, while RVTY trades at $88.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas RVTY's P/E ratio is 43.17. In terms of profitability, PRXL's ROE is +0.17%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, PRXL is less volatile compared to RVTY. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check RVTY's competition here
PRXL vs ICLR Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, ICLR has a market cap of 8.7B. Regarding current trading prices, PRXL is priced at $88.08, while ICLR trades at $114.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas ICLR's P/E ratio is 15.39. In terms of profitability, PRXL's ROE is +0.17%, compared to ICLR's ROE of +0.06%. Regarding short-term risk, PRXL is less volatile compared to ICLR. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check ICLR's competition here
PRXL vs CRL Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, CRL has a market cap of 8.6B. Regarding current trading prices, PRXL is priced at $88.08, while CRL trades at $173.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas CRL's P/E ratio is -59.96. In terms of profitability, PRXL's ROE is +0.17%, compared to CRL's ROE of -0.04%. Regarding short-term risk, PRXL is less volatile compared to CRL. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check CRL's competition here
PRXL vs QGEN Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, QGEN has a market cap of 8.5B. Regarding current trading prices, PRXL is priced at $88.08, while QGEN trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas QGEN's P/E ratio is 20.11. In terms of profitability, PRXL's ROE is +0.17%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, PRXL is less volatile compared to QGEN. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check QGEN's competition here
PRXL vs SYNH Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, PRXL is priced at $88.08, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas SYNH's P/E ratio is 61.40. In terms of profitability, PRXL's ROE is +0.17%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, PRXL is less volatile compared to SYNH. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check SYNH's competition here
PRXL vs SHC Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, SHC has a market cap of 4.3B. Regarding current trading prices, PRXL is priced at $88.08, while SHC trades at $14.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas SHC's P/E ratio is 55.41. In terms of profitability, PRXL's ROE is +0.17%, compared to SHC's ROE of +0.15%. Regarding short-term risk, PRXL is less volatile compared to SHC. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check SHC's competition here
PRXL vs RDNT Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, RDNT has a market cap of 4.3B. Regarding current trading prices, PRXL is priced at $88.08, while RDNT trades at $54.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas RDNT's P/E ratio is -219.16. In terms of profitability, PRXL's ROE is +0.17%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, PRXL is less volatile compared to RDNT. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check RDNT's competition here
PRXL vs BLLN Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, BLLN has a market cap of 3.6B. Regarding current trading prices, PRXL is priced at $88.08, while BLLN trades at $79.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas BLLN's P/E ratio is 566.86. In terms of profitability, PRXL's ROE is +0.17%, compared to BLLN's ROE of +0.01%. Regarding short-term risk, PRXL is less volatile compared to BLLN. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check BLLN's competition here
PRXL vs OLK Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, PRXL is priced at $88.08, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas OLK's P/E ratio is -96.59. In terms of profitability, PRXL's ROE is +0.17%, compared to OLK's ROE of -0.07%. Regarding short-term risk, PRXL is less volatile compared to OLK. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check OLK's competition here
PRXL vs TWST Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, TWST has a market cap of 3.1B. Regarding current trading prices, PRXL is priced at $88.08, while TWST trades at $50.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas TWST's P/E ratio is -39.54. In terms of profitability, PRXL's ROE is +0.17%, compared to TWST's ROE of -0.17%. Regarding short-term risk, PRXL is less volatile compared to TWST. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check TWST's competition here
PRXL vs GRAL Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, GRAL has a market cap of 2.3B. Regarding current trading prices, PRXL is priced at $88.08, while GRAL trades at $54.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas GRAL's P/E ratio is -4.95. In terms of profitability, PRXL's ROE is +0.17%, compared to GRAL's ROE of -0.17%. Regarding short-term risk, PRXL is less volatile compared to GRAL. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check GRAL's competition here
PRXL vs NEOG Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, NEOG has a market cap of 2B. Regarding current trading prices, PRXL is priced at $88.08, while NEOG trades at $9.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas NEOG's P/E ratio is -3.38. In terms of profitability, PRXL's ROE is +0.17%, compared to NEOG's ROE of -0.27%. Regarding short-term risk, PRXL is less volatile compared to NEOG. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check NEOG's competition here
PRXL vs CDNA Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, CDNA has a market cap of 941.7M. Regarding current trading prices, PRXL is priced at $88.08, while CDNA trades at $18.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas CDNA's P/E ratio is -45.77. In terms of profitability, PRXL's ROE is +0.17%, compared to CDNA's ROE of -0.06%. Regarding short-term risk, PRXL is less volatile compared to CDNA. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check CDNA's competition here
PRXL vs OPK Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, OPK has a market cap of 875.2M. Regarding current trading prices, PRXL is priced at $88.08, while OPK trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas OPK's P/E ratio is -3.80. In terms of profitability, PRXL's ROE is +0.17%, compared to OPK's ROE of -0.17%. Regarding short-term risk, PRXL is less volatile compared to OPK. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check OPK's competition here
PRXL vs CSTL Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, CSTL has a market cap of 738.5M. Regarding current trading prices, PRXL is priced at $88.08, while CSTL trades at $24.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas CSTL's P/E ratio is -29.93. In terms of profitability, PRXL's ROE is +0.17%, compared to CSTL's ROE of -0.05%. Regarding short-term risk, PRXL is less volatile compared to CSTL. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check CSTL's competition here
PRXL vs PSNL Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, PSNL has a market cap of 584.3M. Regarding current trading prices, PRXL is priced at $88.08, while PSNL trades at $6.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas PSNL's P/E ratio is -7.23. In terms of profitability, PRXL's ROE is +0.17%, compared to PSNL's ROE of -0.39%. Regarding short-term risk, PRXL is less volatile compared to PSNL. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check PSNL's competition here
PRXL vs GRALV Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, PRXL is priced at $88.08, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas GRALV's P/E ratio is N/A. In terms of profitability, PRXL's ROE is +0.17%, compared to GRALV's ROE of N/A. Regarding short-term risk, PRXL is less volatile compared to GRALV. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check GRALV's competition here
PRXL vs FLGT Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, FLGT has a market cap of 525.3M. Regarding current trading prices, PRXL is priced at $88.08, while FLGT trades at $16.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas FLGT's P/E ratio is -8.54. In terms of profitability, PRXL's ROE is +0.17%, compared to FLGT's ROE of -0.05%. Regarding short-term risk, PRXL is less volatile compared to FLGT. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check FLGT's competition here
PRXL vs ACRS Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, ACRS has a market cap of 506.5M. Regarding current trading prices, PRXL is priced at $88.08, while ACRS trades at $4.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas ACRS's P/E ratio is -7.92. In terms of profitability, PRXL's ROE is +0.17%, compared to ACRS's ROE of -0.52%. Regarding short-term risk, PRXL is less volatile compared to ACRS. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check ACRS's competition here
PRXL vs MYGN Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, MYGN has a market cap of 444.2M. Regarding current trading prices, PRXL is priced at $88.08, while MYGN trades at $4.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas MYGN's P/E ratio is -1.20. In terms of profitability, PRXL's ROE is +0.17%, compared to MYGN's ROE of -0.80%. Regarding short-term risk, PRXL is less volatile compared to MYGN. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check MYGN's competition here
PRXL vs CO Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, PRXL is priced at $88.08, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas CO's P/E ratio is 5.06. In terms of profitability, PRXL's ROE is +0.17%, compared to CO's ROE of +0.11%. Regarding short-term risk, PRXL is less volatile compared to CO. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check CO's competition here
PRXL vs FLDM Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, PRXL is priced at $88.08, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas FLDM's P/E ratio is -4.74. In terms of profitability, PRXL's ROE is +0.17%, compared to FLDM's ROE of -0.18%. Regarding short-term risk, PRXL is less volatile compared to FLDM. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check FLDM's competition here
PRXL vs ATLN Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, ATLN has a market cap of 278.3M. Regarding current trading prices, PRXL is priced at $88.08, while ATLN trades at $3.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas ATLN's P/E ratio is -1.57. In terms of profitability, PRXL's ROE is +0.17%, compared to ATLN's ROE of +6.06%. Regarding short-term risk, PRXL is less volatile compared to ATLN. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check ATLN's competition here
PRXL vs PRE Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, PRE has a market cap of 276.6M. Regarding current trading prices, PRXL is priced at $88.08, while PRE trades at $19.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas PRE's P/E ratio is -5.19. In terms of profitability, PRXL's ROE is +0.17%, compared to PRE's ROE of -0.36%. Regarding short-term risk, PRXL is less volatile compared to PRE. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check PRE's competition here
PRXL vs OPGN Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, OPGN has a market cap of 242.7M. Regarding current trading prices, PRXL is priced at $88.08, while OPGN trades at $23.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas OPGN's P/E ratio is 132.83. In terms of profitability, PRXL's ROE is +0.17%, compared to OPGN's ROE of +0.78%. Regarding short-term risk, PRXL is more volatile compared to OPGN. This indicates potentially higher risk in terms of short-term price fluctuations for PRXL.Check OPGN's competition here
PRXL vs NEO Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, NEO has a market cap of 207.7M. Regarding current trading prices, PRXL is priced at $88.08, while NEO trades at $8.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas NEO's P/E ratio is -9.52. In terms of profitability, PRXL's ROE is +0.17%, compared to NEO's ROE of -0.13%. Regarding short-term risk, PRXL is less volatile compared to NEO. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check NEO's competition here
PRXL vs GTH Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, PRXL is priced at $88.08, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas GTH's P/E ratio is -1.11. In terms of profitability, PRXL's ROE is +0.17%, compared to GTH's ROE of -1.01%. Regarding short-term risk, PRXL is less volatile compared to GTH. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check GTH's competition here
PRXL vs BDSX Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, BDSX has a market cap of 113.8M. Regarding current trading prices, PRXL is priced at $88.08, while BDSX trades at $15.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas BDSX's P/E ratio is -3.23. In terms of profitability, PRXL's ROE is +0.17%, compared to BDSX's ROE of -17.61%. Regarding short-term risk, PRXL is less volatile compared to BDSX. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check BDSX's competition here
PRXL vs GENE Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, PRXL is priced at $88.08, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas GENE's P/E ratio is -38.25. In terms of profitability, PRXL's ROE is +0.17%, compared to GENE's ROE of -1.85%. Regarding short-term risk, PRXL is more volatile compared to GENE. This indicates potentially higher risk in terms of short-term price fluctuations for PRXL.Check GENE's competition here
PRXL vs MDXH Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, MDXH has a market cap of 110.9M. Regarding current trading prices, PRXL is priced at $88.08, while MDXH trades at $2.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas MDXH's P/E ratio is -3.22. In terms of profitability, PRXL's ROE is +0.17%, compared to MDXH's ROE of +5.17%. Regarding short-term risk, PRXL is less volatile compared to MDXH. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check MDXH's competition here
PRXL vs STIM Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, STIM has a market cap of 105.3M. Regarding current trading prices, PRXL is priced at $88.08, while STIM trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas STIM's P/E ratio is -2.58. In terms of profitability, PRXL's ROE is +0.17%, compared to STIM's ROE of -1.39%. Regarding short-term risk, PRXL is less volatile compared to STIM. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check STIM's competition here
PRXL vs SERA Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, SERA has a market cap of 76.7M. Regarding current trading prices, PRXL is priced at $88.08, while SERA trades at $2.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas SERA's P/E ratio is -3.00. In terms of profitability, PRXL's ROE is +0.17%, compared to SERA's ROE of -0.37%. Regarding short-term risk, PRXL is less volatile compared to SERA. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check SERA's competition here
PRXL vs XGN Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, XGN has a market cap of 73.6M. Regarding current trading prices, PRXL is priced at $88.08, while XGN trades at $3.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas XGN's P/E ratio is -3.29. In terms of profitability, PRXL's ROE is +0.17%, compared to XGN's ROE of -1.27%. Regarding short-term risk, PRXL is less volatile compared to XGN. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check XGN's competition here
PRXL vs DRIO Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, DRIO has a market cap of 61.3M. Regarding current trading prices, PRXL is priced at $88.08, while DRIO trades at $8.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas DRIO's P/E ratio is -0.83. In terms of profitability, PRXL's ROE is +0.17%, compared to DRIO's ROE of +0.88%. Regarding short-term risk, PRXL is less volatile compared to DRIO. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check DRIO's competition here
PRXL vs PRPO Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, PRPO has a market cap of 44.5M. Regarding current trading prices, PRXL is priced at $88.08, while PRPO trades at $25.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas PRPO's P/E ratio is -110.43. In terms of profitability, PRXL's ROE is +0.17%, compared to PRPO's ROE of -0.03%. Regarding short-term risk, PRXL is less volatile compared to PRPO. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check PRPO's competition here
PRXL vs STRR Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, STRR has a market cap of 36.1M. Regarding current trading prices, PRXL is priced at $88.08, while STRR trades at $9.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas STRR's P/E ratio is -4.69. In terms of profitability, PRXL's ROE is +0.17%, compared to STRR's ROE of -0.10%. Regarding short-term risk, PRXL is less volatile compared to STRR. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check STRR's competition here
PRXL vs STRRP Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, STRRP has a market cap of 32M. Regarding current trading prices, PRXL is priced at $88.08, while STRRP trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas STRRP's P/E ratio is -5.01. In terms of profitability, PRXL's ROE is +0.17%, compared to STRRP's ROE of -0.10%. Regarding short-term risk, PRXL is less volatile compared to STRRP. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check STRRP's competition here
PRXL vs AKU Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, PRXL is priced at $88.08, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas AKU's P/E ratio is -0.13. In terms of profitability, PRXL's ROE is +0.17%, compared to AKU's ROE of -5.32%. Regarding short-term risk, PRXL is less volatile compared to AKU. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check AKU's competition here
PRXL vs BIAF Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, BIAF has a market cap of 17.6M. Regarding current trading prices, PRXL is priced at $88.08, while BIAF trades at $3.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas BIAF's P/E ratio is -0.45. In terms of profitability, PRXL's ROE is +0.17%, compared to BIAF's ROE of -3.85%. Regarding short-term risk, PRXL is less volatile compared to BIAF. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check BIAF's competition here
PRXL vs BNR Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, BNR has a market cap of 17.4M. Regarding current trading prices, PRXL is priced at $88.08, while BNR trades at $16.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas BNR's P/E ratio is -21.89. In terms of profitability, PRXL's ROE is +0.17%, compared to BNR's ROE of -0.10%. Regarding short-term risk, PRXL is less volatile compared to BNR. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check BNR's competition here
PRXL vs VNRX Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, VNRX has a market cap of 17.1M. Regarding current trading prices, PRXL is priced at $88.08, while VNRX trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas VNRX's P/E ratio is -0.78. In terms of profitability, PRXL's ROE is +0.17%, compared to VNRX's ROE of +0.72%. Regarding short-term risk, PRXL is less volatile compared to VNRX. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check VNRX's competition here
PRXL vs CEMI Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, PRXL is priced at $88.08, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas CEMI's P/E ratio is -0.63. In terms of profitability, PRXL's ROE is +0.17%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, PRXL is more volatile compared to CEMI. This indicates potentially higher risk in terms of short-term price fluctuations for PRXL.Check CEMI's competition here
PRXL vs ENZ Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, PRXL is priced at $88.08, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas ENZ's P/E ratio is -2.24. In terms of profitability, PRXL's ROE is +0.17%, compared to ENZ's ROE of -0.17%. Regarding short-term risk, PRXL is less volatile compared to ENZ. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check ENZ's competition here
PRXL vs PMD Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, PRXL is priced at $88.08, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas PMD's P/E ratio is -5.24. In terms of profitability, PRXL's ROE is +0.17%, compared to PMD's ROE of -0.32%. Regarding short-term risk, PRXL is more volatile compared to PMD. This indicates potentially higher risk in terms of short-term price fluctuations for PRXL.Check PMD's competition here
PRXL vs ME Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, PRXL is priced at $88.08, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas ME's P/E ratio is -0.03. In terms of profitability, PRXL's ROE is +0.17%, compared to ME's ROE of -7.71%. Regarding short-term risk, PRXL is more volatile compared to ME. This indicates potentially higher risk in terms of short-term price fluctuations for PRXL.Check ME's competition here
PRXL vs MBAI Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, MBAI has a market cap of 10.6M. Regarding current trading prices, PRXL is priced at $88.08, while MBAI trades at $1.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas MBAI's P/E ratio is -0.78. In terms of profitability, PRXL's ROE is +0.17%, compared to MBAI's ROE of -2.26%. Regarding short-term risk, PRXL is less volatile compared to MBAI. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check MBAI's competition here
PRXL vs CHEK Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, CHEK has a market cap of 9.8M. Regarding current trading prices, PRXL is priced at $88.08, while CHEK trades at $1.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas CHEK's P/E ratio is -0.39. In terms of profitability, PRXL's ROE is +0.17%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, PRXL is less volatile compared to CHEK. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check CHEK's competition here
PRXL vs CNTG Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, PRXL is priced at $88.08, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas CNTG's P/E ratio is -0.23. In terms of profitability, PRXL's ROE is +0.17%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, PRXL is more volatile compared to CNTG. This indicates potentially higher risk in terms of short-term price fluctuations for PRXL.Check CNTG's competition here
PRXL vs NOTV Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, NOTV has a market cap of 9.2M. Regarding current trading prices, PRXL is priced at $88.08, while NOTV trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas NOTV's P/E ratio is -0.14. In terms of profitability, PRXL's ROE is +0.17%, compared to NOTV's ROE of -0.51%. Regarding short-term risk, PRXL is less volatile compared to NOTV. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check NOTV's competition here
PRXL vs APDN Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, PRXL is priced at $88.08, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas APDN's P/E ratio is -0.10. In terms of profitability, PRXL's ROE is +0.17%, compared to APDN's ROE of -8.97%. Regarding short-term risk, PRXL is less volatile compared to APDN. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check APDN's competition here
PRXL vs TRIB Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, TRIB has a market cap of 6.3M. Regarding current trading prices, PRXL is priced at $88.08, while TRIB trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas TRIB's P/E ratio is -0.38. In terms of profitability, PRXL's ROE is +0.17%, compared to TRIB's ROE of +0.81%. Regarding short-term risk, PRXL is less volatile compared to TRIB. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check TRIB's competition here
PRXL vs QUCY Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, QUCY has a market cap of 5.7M. Regarding current trading prices, PRXL is priced at $88.08, while QUCY trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas QUCY's P/E ratio is -0.02. In terms of profitability, PRXL's ROE is +0.17%, compared to QUCY's ROE of -4.66%. Regarding short-term risk, PRXL is less volatile compared to QUCY. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check QUCY's competition here
PRXL vs NVTA Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, PRXL is priced at $88.08, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas NVTA's P/E ratio is -0.00. In terms of profitability, PRXL's ROE is +0.17%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, PRXL is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check NVTA's competition here
PRXL vs LMDXW Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, PRXL is priced at $88.08, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, PRXL's ROE is +0.17%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, PRXL is less volatile compared to LMDXW. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check LMDXW's competition here
PRXL vs LMDX Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, PRXL is priced at $88.08, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas LMDX's P/E ratio is -0.01. In terms of profitability, PRXL's ROE is +0.17%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, PRXL is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check LMDX's competition here
PRXL vs ADVB Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, ADVB has a market cap of 4.9M. Regarding current trading prices, PRXL is priced at $88.08, while ADVB trades at $4.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas ADVB's P/E ratio is 1.29. In terms of profitability, PRXL's ROE is +0.17%, compared to ADVB's ROE of +1.01%. Regarding short-term risk, PRXL is less volatile compared to ADVB. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check ADVB's competition here
PRXL vs BGLC Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, BGLC has a market cap of 4M. Regarding current trading prices, PRXL is priced at $88.08, while BGLC trades at $2.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas BGLC's P/E ratio is -1.73. In terms of profitability, PRXL's ROE is +0.17%, compared to BGLC's ROE of -0.30%. Regarding short-term risk, PRXL is less volatile compared to BGLC. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check BGLC's competition here
PRXL vs BNGO Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, BNGO has a market cap of 3.9M. Regarding current trading prices, PRXL is priced at $88.08, while BNGO trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas BNGO's P/E ratio is -0.25. In terms of profitability, PRXL's ROE is +0.17%, compared to BNGO's ROE of -0.56%. Regarding short-term risk, PRXL is less volatile compared to BNGO. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check BNGO's competition here
PRXL vs NDRA Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, NDRA has a market cap of 3.5M. Regarding current trading prices, PRXL is priced at $88.08, while NDRA trades at $4.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas NDRA's P/E ratio is 0.24. In terms of profitability, PRXL's ROE is +0.17%, compared to NDRA's ROE of -4.97%. Regarding short-term risk, PRXL is less volatile compared to NDRA. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check NDRA's competition here
PRXL vs DMTK Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, PRXL is priced at $88.08, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas DMTK's P/E ratio is -0.04. In terms of profitability, PRXL's ROE is +0.17%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, PRXL is less volatile compared to DMTK. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check DMTK's competition here
PRXL vs MYNZ Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, MYNZ has a market cap of 2.9M. Regarding current trading prices, PRXL is priced at $88.08, while MYNZ trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas MYNZ's P/E ratio is -0.13. In terms of profitability, PRXL's ROE is +0.17%, compared to MYNZ's ROE of -10.25%. Regarding short-term risk, PRXL is less volatile compared to MYNZ. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check MYNZ's competition here
PRXL vs SQL Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, PRXL is priced at $88.08, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas SQL's P/E ratio is -0.40. In terms of profitability, PRXL's ROE is +0.17%, compared to SQL's ROE of +9.82%. Regarding short-term risk, PRXL is less volatile compared to SQL. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check SQL's competition here
PRXL vs AWH Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, PRXL is priced at $88.08, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas AWH's P/E ratio is -0.09. In terms of profitability, PRXL's ROE is +0.17%, compared to AWH's ROE of +3.65%. Regarding short-term risk, PRXL is more volatile compared to AWH. This indicates potentially higher risk in terms of short-term price fluctuations for PRXL.Check AWH's competition here
PRXL vs INBS Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, INBS has a market cap of 1.8M. Regarding current trading prices, PRXL is priced at $88.08, while INBS trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas INBS's P/E ratio is -0.19. In terms of profitability, PRXL's ROE is +0.17%, compared to INBS's ROE of -1.98%. Regarding short-term risk, PRXL is less volatile compared to INBS. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check INBS's competition here
PRXL vs BIAFW Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, BIAFW has a market cap of 1.3M. Regarding current trading prices, PRXL is priced at $88.08, while BIAFW trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas BIAFW's P/E ratio is N/A. In terms of profitability, PRXL's ROE is +0.17%, compared to BIAFW's ROE of -3.85%. Regarding short-term risk, PRXL is less volatile compared to BIAFW. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check BIAFW's competition here
PRXL vs HTGM Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, PRXL is priced at $88.08, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas HTGM's P/E ratio is -0.03. In terms of profitability, PRXL's ROE is +0.17%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, PRXL is more volatile compared to HTGM. This indicates potentially higher risk in terms of short-term price fluctuations for PRXL.Check HTGM's competition here
PRXL vs ISPC Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, ISPC has a market cap of 789.8K. Regarding current trading prices, PRXL is priced at $88.08, while ISPC trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas ISPC's P/E ratio is -0.06. In terms of profitability, PRXL's ROE is +0.17%, compared to ISPC's ROE of -5.46%. Regarding short-term risk, PRXL is less volatile compared to ISPC. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check ISPC's competition here
PRXL vs BIOC Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, PRXL is priced at $88.08, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas BIOC's P/E ratio is -0.01. In terms of profitability, PRXL's ROE is +0.17%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, PRXL is less volatile compared to BIOC. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check BIOC's competition here
PRXL vs PRENW Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, PRENW has a market cap of 253K. Regarding current trading prices, PRXL is priced at $88.08, while PRENW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas PRENW's P/E ratio is N/A. In terms of profitability, PRXL's ROE is +0.17%, compared to PRENW's ROE of -0.36%. Regarding short-term risk, PRXL is more volatile compared to PRENW. This indicates potentially higher risk in terms of short-term price fluctuations for PRXL.Check PRENW's competition here
PRXL vs SQLLW Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, SQLLW has a market cap of 159.3K. Regarding current trading prices, PRXL is priced at $88.08, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas SQLLW's P/E ratio is -0.01. In terms of profitability, PRXL's ROE is +0.17%, compared to SQLLW's ROE of +6.06%. Regarding short-term risk, PRXL is less volatile compared to SQLLW. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check SQLLW's competition here
PRXL vs TTOO Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, TTOO has a market cap of 5.6K. Regarding current trading prices, PRXL is priced at $88.08, while TTOO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas TTOO's P/E ratio is -0.01. In terms of profitability, PRXL's ROE is +0.17%, compared to TTOO's ROE of +1.47%. Regarding short-term risk, PRXL is less volatile compared to TTOO. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check TTOO's competition here
PRXL vs CHEKZ Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, PRXL is priced at $88.08, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, PRXL's ROE is +0.17%, compared to CHEKZ's ROE of -2.26%. Regarding short-term risk, PRXL is less volatile compared to CHEKZ. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check CHEKZ's competition here
PRXL vs BNGOW Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, PRXL is priced at $88.08, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas BNGOW's P/E ratio is N/A. In terms of profitability, PRXL's ROE is +0.17%, compared to BNGOW's ROE of -0.56%. Regarding short-term risk, PRXL is less volatile compared to BNGOW. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check BNGOW's competition here
PRXL vs DHR-PA Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, PRXL is priced at $88.08, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, PRXL's ROE is +0.17%, compared to DHR-PA's ROE of +0.07%. Regarding short-term risk, PRXL is less volatile compared to DHR-PA. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check DHR-PA's competition here
PRXL vs OCDX Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, OCDX has a market cap of 0. Regarding current trading prices, PRXL is priced at $88.08, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas OCDX's P/E ratio is -42.28. In terms of profitability, PRXL's ROE is +0.17%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, PRXL is less volatile compared to OCDX. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check OCDX's competition here
PRXL vs MEUSW Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, PRXL is priced at $88.08, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas MEUSW's P/E ratio is N/A. In terms of profitability, PRXL's ROE is +0.17%, compared to MEUSW's ROE of -7.71%. Regarding short-term risk, PRXL is less volatile compared to MEUSW. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check MEUSW's competition here
PRXL vs NDRAW Comparison April 2026
PRXL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, PRXL is priced at $88.08, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of N/A, whereas NDRAW's P/E ratio is N/A. In terms of profitability, PRXL's ROE is +0.17%, compared to NDRAW's ROE of -4.97%. Regarding short-term risk, PRXL is less volatile compared to NDRAW. This indicates potentially lower risk in terms of short-term price fluctuations for PRXL.Check NDRAW's competition here